Future cardiology最新文献_第7页

Post-myocardial infarction complications in patients with inflammatory bowel disease: a retrospective cohort study using the National Inpatient Sample (2016-2022). 炎症性肠病患者心肌梗死后并发症：一项使用全国住院患者样本（2016-2022）的回顾性队列研究

IF 1.1

Future cardiology Pub Date : 2026-04-01 Epub Date: 2026-03-02 DOI: 10.1080/14796678.2026.2639403

Omar Alkasabrah, Siddharth Pravin Agrawal, Abdullah Hafeez, Ahmed Farid Gadelmawla, Yasmine Adel Mohammed, Marina Takawy, Sameeha Ibrahim, Dhruvi K Joshi, Hritvik Jain, Wilbert S Aronow

{"title":"Post-myocardial infarction complications in patients with inflammatory bowel disease: a retrospective cohort study using the National Inpatient Sample (2016-2022).","authors":"Omar Alkasabrah, Siddharth Pravin Agrawal, Abdullah Hafeez, Ahmed Farid Gadelmawla, Yasmine Adel Mohammed, Marina Takawy, Sameeha Ibrahim, Dhruvi K Joshi, Hritvik Jain, Wilbert S Aronow","doi":"10.1080/14796678.2026.2639403","DOIUrl":"10.1080/14796678.2026.2639403","url":null,"abstract":"Background: Inflammatory bowel disease (IBD) is associated with systemic inflammation and increased cardiovascular risk, but its impact on in-hospital outcomes after acute myocardial infarction (MI) remains unclear.Methods: We conducted a retrospective cohort study using the National Inpatient Sample (2016-2022) to identify hospitalizations for acute MI and compared outcomes between patients with and without IBD. Multivariate logistic regression was used to evaluate the association between IBD and post-MI complications. Associations were summarized as adjusted odds ratios (aORs) with 95% confidence intervals (CIs).Results: Among 1,456,940 MI hospitalizations, 7,430 had IBD. After adjustment, IBD was associated with higher odds of mortality (aOR 3.32, 95% CI 3.18-3.47; p < 0.0001), left ventricular rupture (aOR 4.46, 95% CI 3.16-6.28; p < 0.0001), left ventricular aneurysm (aOR 1.93, 95% CI 1.61-2.31; p < 0.0001), acute mitral regurgitation (aOR 9.80, 95% CI 6.81-14.10; p < 0.0001), and stent restenosis (aOR 1.16, 95% CI 1.07-1.26; p = 0.0002). IBD was also associated with longer hospital stay (coefficient 2.13 days, 95% CI 2.03-2.23; p < 0.0001) and higher total hospital charges.Conclusion: IBD was associated with worse in-hospital outcomes and higher resource utilization after MI in this nationwide hospitalization-level analysis.","PeriodicalId":12589,"journal":{"name":"Future cardiology","volume":" ","pages":"363-371"},"PeriodicalIF":1.1,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13185456/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147344155","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Decoding Kounis syndrome with artificial intelligence: from diagnosis to precision medicine. 用人工智能解码库尼斯综合征：从诊断到精准医疗。

IF 1.1

Future cardiology Pub Date : 2026-04-01 Epub Date: 2026-04-29 DOI: 10.1080/14796678.2026.2659086

George Kipourgos, Anastasios Tzenalis, Efthymia Andrikopoulou-Gkila, Nicholas G Kounis

{"title":"Decoding Kounis syndrome with artificial intelligence: from diagnosis to precision medicine.","authors":"George Kipourgos, Anastasios Tzenalis, Efthymia Andrikopoulou-Gkila, Nicholas G Kounis","doi":"10.1080/14796678.2026.2659086","DOIUrl":"10.1080/14796678.2026.2659086","url":null,"abstract":"Kounis syndrome-acute coronary events triggered by allergic or hypersensitivity reactions-remains underrecognized across emergency and cardiology settings. Its heterogeneous presentation and overlapping mechanisms (vasospasm, plaque erosion/rupture, stent thrombosis) challenge timely diagnosis and tailored therapy.This review synthesizes contemporary evidence on pathophysiology, clinical spectrum, and management of Kounis syndrome (Types I-III), and map how artificial intelligence (AI) could enhance care pathways. We outline data streams relevant to AI (ECG, biomarkers, imaging, clinical narratives), modeling approaches (machine learning, sequence models), and decision-support scenarios (early detection, risk stratification, treatment selection, and monitoring). We also address implementation barriers, including dataset shift, bias, transparency, and governance.Kounis syndrome is a prime candidate for AI-enabled diagnostic support given its pattern-based signatures at the interface of allergy and acute coronary syndromes. Near-term priorities include curated multicenter datasets with harmonized phenotyping, prospective validation of models embedded in clinical workflows, and hybrid rules-plus-learning systems aligned with guideline-based care. Integrating allergy severity, hemodynamics, and ischemic burden into dynamic risk tools may reduce missed diagnoses and optimize anti-allergic and antithrombotic strategies while safeguarding patient safety.","PeriodicalId":12589,"journal":{"name":"Future cardiology","volume":" ","pages":"405-415"},"PeriodicalIF":1.1,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13185448/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147768543","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Diagnostic and treatment approaches of cardiac amyloidosis with wild-type and mutated transthyretin. 野生型和突变甲状腺素型心脏淀粉样变性的诊断和治疗方法。

IF 1

Future cardiology Pub Date : 2026-04-01 Epub Date: 2026-02-19 DOI: 10.1080/14796678.2026.2631534

Ronja Flueren, Ibrahim Akin, Nazha Hamdani, Ibrahim El-Battrawy

引用次数: 0

Safety and efficacy of percutaneous patent foramen ovale closure compared with anti-thrombotic therapy for people with cryptogenic stroke: a systematic review and meta-analysis. 与抗血栓治疗相比，经皮卵圆孔未闭治疗对隐源性卒中患者的安全性和有效性：一项系统回顾和荟萃分析。

IF 1.1

Future cardiology Pub Date : 2026-04-01 Epub Date: 2026-05-08 DOI: 10.1080/14796678.2026.2665753

Jay Tewari, Harsh Agrawal, Pooja Dubey, Alok Dwivedi, Shubhechha Neupane, Vanshika Singh, Indika Mallawaarachchi, Debabrata Mukherjee

{"title":"Safety and efficacy of percutaneous patent foramen ovale closure compared with anti-thrombotic therapy for people with cryptogenic stroke: a systematic review and meta-analysis.","authors":"Jay Tewari, Harsh Agrawal, Pooja Dubey, Alok Dwivedi, Shubhechha Neupane, Vanshika Singh, Indika Mallawaarachchi, Debabrata Mukherjee","doi":"10.1080/14796678.2026.2665753","DOIUrl":"10.1080/14796678.2026.2665753","url":null,"abstract":"Background: Stroke is a leading cause of death and disability. Patent foramen ovale (PFO) is more common in cryptogenic stroke, but the benefit of closure over antithrombotic therapy remains debated. We updated randomized evidence comparing PFO closure with antithrombotic therapy.Methods: MEDLINE, Embase, and Cochrane Central were searched through September 2025. Primary outcomes were stroke, transient ischemic attack (TIA), and a composite of stroke, TIA, death, or systemic embolism. Serious adverse events and atrial fibrillation were assessed.Results: Six trials (n = 3,560; closure 1,889; therapy 1,671) were included. Composite events occurred in 84 (4.4%) vs 152 (9.1%). Closure reduced the composite endpoint (HR 0.46, 95% CI 0.28-0.75; p = 0.002) and recurrent stroke (37 [2.0%] vs 77 [4.6%]; HR 0.27, 95% CI 0.12-0.62; p = 0.002). Benefit was greatest in men, age <45 years, and those with large shunts. Serious adverse events and mortality were similar, but atrial fibrillation increased (HR 4.46, 95% CI 2.00-9.92; p < 0.001).Conclusion: In selected patients, PFO closure lowers recurrent stroke and composite events versus antithrombotic therapy, at the cost of higher atrial fibrillation.Protocol registration: www.crd.york.ac.uk/prospero identifier is CRD420251167260.","PeriodicalId":12589,"journal":{"name":"Future cardiology","volume":" ","pages":"373-382"},"PeriodicalIF":1.1,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13185451/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147836673","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Granulocyte colony stimulating factor for acute myocardial infarction: an updated systematic review and meta-analysis of randomized controlled trials. 急性心肌梗死的粒细胞集落刺激因子：随机对照试验的最新系统评价和荟萃分析。

IF 1.1

Future cardiology Pub Date : 2026-04-01 Epub Date: 2026-04-17 DOI: 10.1080/14796678.2026.2655394

Luiz Guilherme Silva Almeida, Lucca Tamara Alves Carretta, Luciano Falcão, Adolfo Moraes de Souza, Yasmin Picanço Silva, Mariana Pulrolnik Parrillo de Oliveira, Ricardo F O Suruagy-Motta, Karlos Daniell Araújo Dos Santos, Rafael Torres Fonseca Dos Santos, Gustavo Surgik, Fernanda Almeida Andrade

{"title":"Granulocyte colony stimulating factor for acute myocardial infarction: an updated systematic review and meta-analysis of randomized controlled trials.","authors":"Luiz Guilherme Silva Almeida, Lucca Tamara Alves Carretta, Luciano Falcão, Adolfo Moraes de Souza, Yasmin Picanço Silva, Mariana Pulrolnik Parrillo de Oliveira, Ricardo F O Suruagy-Motta, Karlos Daniell Araújo Dos Santos, Rafael Torres Fonseca Dos Santos, Gustavo Surgik, Fernanda Almeida Andrade","doi":"10.1080/14796678.2026.2655394","DOIUrl":"10.1080/14796678.2026.2655394","url":null,"abstract":"Introduction: Granulocyte Colony-Stimulating Factor (G-CSF) has been explored as a therapy to enhance myocardial repair after acute myocardial infarction (AMI). Earlier meta-analyses of randomized controlled trials (RCTs) reported no significant improvement but recently published studies warranted an updated synthesis.Methods: We searched PubMed, Embase, Cochrane Library, and Web of Science for RCTs comparing G-CSF with placebo or standard care in AMI. Primary outcomes were left ventricular end-diastolic volume (LVEDV), left ventricular end-systolic volume (LVESV), and left ventricular ejection fraction (LVEF). Secondary outcomes were mortality, reinfarction, restenosis, and revascularization.Results: Eleven RCTs encompassing 1,073 participants were included. G-CSF significantly reduced LVEDV in echocardiography studies (MD: -4.39 mL; 95% CI -6.80, -1.98; p < 0.001), whereas no effect was observed in MRI studies (MD: -0.19 mL; 95% CI -7.22, 6.84; p = 0.958). LVEF improved in the echocardiography subgroup (MD: 6.76%; 95% CI 1.62, 11.90; p = 0.010) but not in the MRI subgroup (MD: -0.08%; 95% CI -2.38, 2.22; p = 0.947). LVESV showed no significant differences. No effects were seen for mortality, reinfarction, restenosis, or revascularization.Conclusion: G-CSF may confer structural benefits detectable by echocardiography, yet clinical outcomes remain unchanged. Larger, high-quality trials are needed to define its therapeutic role.","PeriodicalId":12589,"journal":{"name":"Future cardiology","volume":" ","pages":"391-404"},"PeriodicalIF":1.1,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13185460/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147698470","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Treatment with finerenone in people with heart failure and mildly reduced or preserved ejection fraction: a plain language review. 细芬烯酮治疗心力衰竭患者并轻度降低或保留射血分数：一项简单的语言回顾。

IF 1

Future cardiology Pub Date : 2026-04-01 Epub Date: 2026-04-28 DOI: 10.1080/14796678.2026.2650667

Marc Bains, Jawad H Butt, John W Ostrominski, Maria A Pabon Porras, Laurence Humphreys-Davies

引用次数: 0

Predicting adverse outcomes after cardiac surgery and structural interventions: the role of right ventricular function. 预测心脏手术和结构性干预后的不良后果：右心室功能的作用。

IF 1.1

Future cardiology Pub Date : 2026-04-01 Epub Date: 2026-03-25 DOI: 10.1080/14796678.2026.2643096

Eszter Pál, Veronika Párkányi, Tímea Katalin Turschl, Alexandra Fábián, Andrea Ferencz, Márton Tokodi, Máté Tolvaj, Andrea Nagy, Attila Kovács, Béla Merkely, Bálint Károly Lakatos, Zsuzsanna Ladányi

{"title":"Predicting adverse outcomes after cardiac surgery and structural interventions: the role of right ventricular function.","authors":"Eszter Pál, Veronika Párkányi, Tímea Katalin Turschl, Alexandra Fábián, Andrea Ferencz, Márton Tokodi, Máté Tolvaj, Andrea Nagy, Attila Kovács, Béla Merkely, Bálint Károly Lakatos, Zsuzsanna Ladányi","doi":"10.1080/14796678.2026.2643096","DOIUrl":"10.1080/14796678.2026.2643096","url":null,"abstract":"Right ventricular (RV) function is a major determinant of clinical outcomes in patients undergoing cardiac surgery and transcatheter interventions. Although left ventricular morphology and function have been the traditional focus of preprocedural assessment, RV dysfunction is now recognized as an important predictor of morbidity and mortality. Therefore, inclusion of RV-related parameters in preprocedural risk assessment is on the rise. This review summarizes current evidence on the role of RV function in various cardiac diseases that require surgery or interventions. Conventional two-dimensional echocardiographic parameters, such as tricuspid annular plane systolic excursion, RV fractional area change, and peak systolic tissue Doppler velocity, provide limited information due to the complex RV geometry. Advanced imaging techniques, including speckle-tracking, three-dimensional echocardiography, and cardiac magnetic resonance imaging, enable more accurate quantification of RV volumes, ejection fraction, strain, RV motion components and RV-pulmonary artery coupling, and have demonstrated superior prognostic value. Therefore, a comprehensive assessment of RV function using advanced imaging techniques should be incorporated into routine clinical practice to improve risk stratification and preprocedural planning before cardiac surgery and transcatheter interventions. However, it is necessary to standardize imaging protocols and define validated reference thresholds to support the clinical implementation of these state-of-the-art parameters.","PeriodicalId":12589,"journal":{"name":"Future cardiology","volume":" ","pages":"417-429"},"PeriodicalIF":1.1,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13185435/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147511326","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Adipose tissue-derived mesenchymal stromal cell therapy in nonischemic heart failure with reduced ejection fraction - ARIISE study design. 脂肪组织源性间充质细胞治疗非缺血性心力衰竭伴射血分数降低- ARIISE研究设计。

IF 1.1

Future cardiology Pub Date : 2026-04-01 Epub Date: 2026-03-25 DOI: 10.1080/14796678.2026.2647879

Nadia Chaaban, Jens Kastrup, Kasper Rossing, Morten Schou, Jens Hove, Pernille Buch, Annette Ekblond, Ellen Mønsted Johansen, Morten Juhl Nørgaard, Lisbeth Drozd Højgaard, Abbas Ali Qayyum

{"title":"Adipose tissue-derived mesenchymal stromal cell therapy in nonischemic heart failure with reduced ejection fraction - ARIISE study design.","authors":"Nadia Chaaban, Jens Kastrup, Kasper Rossing, Morten Schou, Jens Hove, Pernille Buch, Annette Ekblond, Ellen Mønsted Johansen, Morten Juhl Nørgaard, Lisbeth Drozd Højgaard, Abbas Ali Qayyum","doi":"10.1080/14796678.2026.2647879","DOIUrl":"10.1080/14796678.2026.2647879","url":null,"abstract":"Heart failure (HF) remains a major clinical and healthcare challenge with high morbidity, mortality, and impaired quality of life (QOL). Approximately 30-40% of HF cases in the western world are of nonischemic heart failure (NIHF) origin; yet, regenerative therapies are lacking. Evidence suggests that systemic inflammation contributes to disease progression in NIHF, highlighting immunomodulation as a potential therapeutic target. Mesenchymal stromal cells (MSCs) possess regenerative and immunomodulatory properties, with adipose tissue derived stromal cells (ASCs) emerging as particularly promising. ARIISE is a Danish, multicenter, randomized, double-blinded, placebo-controlled study evaluating the efficacy and safety of intravenous allogeneic ASC therapy (C2C_ASC110) in patients with NIHF and reduced left ventricular ejection fraction (LVEF ≤ 45%). Ninety patients will be randomized to receive either C2C_ASC110 or placebo dimethyl sulfoxide (DMSO) (Cryostor®) intravenously twice 1 month apart, in addition to optimal guideline-directed medical therapy. The primary endpoint is a change in LVEF at 6-month follow-up after second ASC/placebo infusion. Secondary endpoints include other echocardiographic measurements, functional capacity, biomarkers, quality of life (QOL), and safety outcomes. If successful, ARIISE may establish clinical evidence for intravenous ASC therapy as a safe, feasible, and effective regenerative treatment for patients with NIHF.Clinical trial registration: EU CT number: 2025-520837-22-00, UTN number: U1111-1315-7011, Clinicaltrials.gov number: NCT06840275.","PeriodicalId":12589,"journal":{"name":"Future cardiology","volume":" ","pages":"353-361"},"PeriodicalIF":1.1,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13185433/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147511267","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Mapping and evaluation of global and country-specific cardiovascular disease risk prediction models. 绘制和评估全球和特定国家心血管疾病风险预测模型。

IF 1.1

Future cardiology Pub Date : 2026-04-01 Epub Date: 2026-03-17 DOI: 10.1080/14796678.2026.2645012

Samina Akhtar, Zainab Samad, Gerald S Bloomfield, Salim S Virani, Aysha Almas

{"title":"Mapping and evaluation of global and country-specific cardiovascular disease risk prediction models.","authors":"Samina Akhtar, Zainab Samad, Gerald S Bloomfield, Salim S Virani, Aysha Almas","doi":"10.1080/14796678.2026.2645012","DOIUrl":"10.1080/14796678.2026.2645012","url":null,"abstract":"Cardiovascular diseases (CVDs) remain a leading cause of global morbidity and mortality, requiring precise risk prediction models for effective prevention and management. This review maps and evaluates globally utilized and country-specific CVD risk prediction models, including the Framingham Risk Score, Pooled Cohort Equations, PREVENT, WHO/ISH Risk Charts, INTERHEART, and SCORE2. A structured literature search was conducted using PubMed and Google Scholar, from which 30 relevant studies were selected. Most of the models integrate traditional risk factors such as age, sex, blood pressure, cholesterol, and smoking status to estimate CVD risk. While these models demonstrate moderate to good discrimination (C-statistics ranging from 0.66 to 0.80) and validation, their applicability varies across populations, with concerns about overestimation or underestimation in non-original cohorts. Notably, the WHO/ISH and Globorisk models address global diversity by incorporating regional calibrations, making them suitable for low- and middle-income countries. Similarly, the country-specific risk scores outperform global models due to their incorporation of local socio-demographics. Limitations persist across existing models, including the underrepresentation of younger individuals, ethnic minorities, and the exclusion of emerging risk factors. Future efforts must prioritize the development of locally validated, population-specific models to support equitable and effective CVD risk assessment and prevention.","PeriodicalId":12589,"journal":{"name":"Future cardiology","volume":" ","pages":"431-440"},"PeriodicalIF":1.1,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13102548/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147467551","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Omega-3 polyunsaturated fatty acid exposure and cardiovascular outcomes in dialysis: a systematic review and meta-analysis. Omega-3多不饱和脂肪酸暴露与透析心血管结局：系统回顾和荟萃分析。

IF 1.1

Future cardiology Pub Date : 2026-04-01 Epub Date: 2026-03-18 DOI: 10.1080/14796678.2026.2645005

Arveen Shokravi, Sohat Sharma, Rishav Singh, Jayant Seth, G B John Mancini

{"title":"Omega-3 polyunsaturated fatty acid exposure and cardiovascular outcomes in dialysis: a systematic review and meta-analysis.","authors":"Arveen Shokravi, Sohat Sharma, Rishav Singh, Jayant Seth, G B John Mancini","doi":"10.1080/14796678.2026.2645005","DOIUrl":"10.1080/14796678.2026.2645005","url":null,"abstract":"Background: Patients with dialysis-dependent chronic kidney disease (CKD) have a high cardiovascular burden, prompting interest in fish oils or long-chain omega-3 polyunsaturated fatty acids (n-3 PUFAs) as potential risk-reducing therapies in this population.Methods: We conducted a systematic review and meta-analysis of studies in adults receiving dialysis that assessed associations between n-3 PUFA supplementation, baseline levels, or dietary intake and CV outcomes, or all-cause mortality. Hazard ratios (HRs) were pooled using random-effects models.Results: Twelve studies met inclusion criteria. In hemodialysis-dependent CKD, fish oil supplementation lowered cardiovascular events by 44% (HR 0.56; 95% CI 0.46-0.68) and myocardial infarction by 48% (HR 0.52; 95% CI 0.34-0.78). Higher baseline n-3 PUFA levels were associated with a 31% reduction in all-cause mortality (HR 0.69; 95% CI 0.54-0.88). Higher dietary n-3 PUFA intake showed a non-significant trend toward lower all-cause mortality (HR 0.92; 95% CI 0.79-1.08).Conclusion: In dialysis-dependent CKD, higher n-3 PUFA exposure through fish oil supplementation or higher baseline levels was associated with fewer cardiovascular events and all-cause mortality. Appropriately dosed n-3 PUFA supplementation represents a promising cardiovascular risk reduction strategy in dialysis-dependent CKD, although confirmatory randomized trials are warranted.","PeriodicalId":12589,"journal":{"name":"Future cardiology","volume":" ","pages":"383-390"},"PeriodicalIF":1.1,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13185434/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147479590","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0